CryoPort, Inc. (NASDAQ:CYRX) Stock Has Consensus Price Target of $18.38 According to Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on CryoPort, with seven buy ratings, one hold and one sell. The average 12-month price target is $18.38, versus a reported opening price of $16.90.
• CryoPort’s latest quarterly results slightly missed earnings expectations, reporting a loss of $0.20 per share versus the $0.19 consensus estimate, while revenue of $48.97 million exceeded forecasts. The company remains unprofitable, with a negative net margin of 20.05%.
• CEO Jerrell Shelton sold 28,800 shares under a pre-arranged Rule 10b5-1 plan, while institutional investors own 92.9% of the stock. CryoPort provides temperature-controlled logistics and storage solutions for advanced therapies and other sensitive life-science materials.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.38.

A number of equities research analysts have issued reports on the stock. Needham & Company LLC lifted their target price on shares of CryoPort from $15.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Roth Capital reiterated a "buy" rating and set a $21.00 price objective on shares of CryoPort in a report on Friday, August 7th. BTIG Research reissued a "buy" rating and set a $25.00 price objective on shares of CryoPort in a research report on Friday, September 18th. Weiss Ratings downgraded CryoPort from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, August 17th. Finally, Guggenheim upped their target price on CryoPort from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st.

CryoPort Trading Down 2.6%

Shares of NASDAQ CYRX opened at $16.90 on Friday. CryoPort has a one year low of $7.61 and a one year high of $18.36. The business has a 50-day moving average price of $16.24 and a two-hundred day moving average price of $14.28. The firm has a market capitalization of $855.98 million, a PE ratio of -18.78 and a beta of 1.96.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The business had revenue of $48.97 million during the quarter, compared to analyst estimates of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. Research analysts anticipate that CryoPort will post -0.83 EPS for the current year.

Insider Activity at CryoPort

In related news, CEO Jerrell Shelton sold 28,800 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the sale, the chief executive officer owned 1,201,814 shares of the company's stock, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company's stock.

Institutional Trading of CryoPort

A number of institutional investors have recently added to or reduced their stakes in CYRX. Engineers Gate Manager LP acquired a new stake in shares of CryoPort in the 2nd quarter valued at $518,000. Squarepoint Ops LLC raised its holdings in CryoPort by 685.1% during the second quarter. Squarepoint Ops LLC now owns 368,424 shares of the company's stock valued at $5,784,000 after buying an additional 321,497 shares in the last quarter. Highland Investment Advisors LLC acquired a new stake in shares of CryoPort in the second quarter worth about $306,000. Kerrisdale Advisers LLC bought a new stake in shares of CryoPort during the 2nd quarter worth about $355,000. Finally, Headlands Technologies LLC increased its holdings in shares of CryoPort by 14.5% during the 2nd quarter. Headlands Technologies LLC now owns 38,742 shares of the company's stock valued at $608,000 after acquiring an additional 4,906 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Company Profile

CryoPort, Inc is a life sciences logistics company that provides temperature-controlled supply chain solutions for the development, manufacture and delivery of advanced therapies, biologics and other temperature-sensitive materials. Its services are used in areas including cell and gene therapy, regenerative medicine, pharmaceuticals, clinical research and reproductive medicine.

The company offers specialized shipping systems, cryogenic storage and monitoring technologies, logistics coordination, inventory management and related support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.